-
Infographic – US Biotech Venture Deals Slow in Q1
The rate of new venture deals for biotechnology start-ups in the U.S. slowed in the first quarter of 2022, but total dollars invested remain on track from last year.
-
Ginkgo Acquires Bayer Agricultural Biologics Technology
Synthetic biology developer Ginkgo Bioworks is acquiring agricultural biologics assets from Bayer, transforming the companies’ five-year partnership.
-
Post removed
Sponsored post removed for non-payment. * * *
-
Health Blockchain Start-Up Raises $5.5M in Seed Funds
A new enterprise aggregating and securing a wide range of health care data with blockchain technology is raising $5.5 million in seed funds.
-
Trial Begins Testing Crispr Gut Microbiome Therapy
A clinical trial is underway assessing a genetically edited oral drug designed to remove E. coli in the gut, a danger for patients with blood-related cancers.
-
Cystic Fibrosis Start-Up Raises $111M in New Funds
A developer of new treatments for the inherited lung disease cystic fibrosis emerged from stealth mode, raising $111 million in new venture funds.
-
Trial Set for Gut Infection Biologic Treatment
A developer of biologic therapies for gastrointestinal disorders says FDA cleared its request for a clinical trial testing its treatment for C. difficile.
-
Infographic – Chill Descends on Q1 Venture Funds
The rise in venture funds invested in start-up businesses worldwide over the past two years took a noticeable downturn in the first three months of 2022.
-
Biotech Start-Up Begins Longevity Therapy Work
A new biotechnology company has begun developing gene therapies aimed at reprogramming cells damaged by the aging process.
-
Gates Funds Engineered Malaria Mosquito Pilot Test
A developer of genetically altered insects designed to destroy disease-spreading colonies is set to begin pilot tests of its anti-malarial mosquito line.